Gemcitabine-Induced Thrombotic Microangiopathy: A Case Report
We report the case of a 69-year-old woman with metastatic lung adenocarcinoma who developed severe thrombotic microangiopathy (TMA) only seven days after receiving her first dose of gemcitabine. The patient had pre-existing stage 3a chronic kidney disease and previous exposure to bevacizumab, which may have increased h...